The purpose of this Phase 3 study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe Systemic Lupus Erythematosus (SLE) population.
To Learn More Contact:
The BMS Study Connect Contact Center at www.BMSStudyConnect.com or call 855-907-3286 or email Clinical.Trials@bms.com. First line of the email must contain the NCT number and the number of the trial site.
ClinicalTrials.gov identifier (NCT number): NCT05620407